

MINUTE
AREA DRUG AND THERAPEUTICS COMMITTEE
WEDNESDAY 18th May 2022 @10am
Microsoft Teams Meeting

In Attendance:

Dr Mehrdad Malekian	Mrs Karen Patterson	Mrs Christine Gilmour
Mr George Lindsay	Dr Stephanie Dundas	Mr John Milne
Mrs Katrina Maroni	Mrs Carol McGoff	Mrs Emma Harris
Mrs Gail Richardson	Mrs Penny Brankin	Mrs Linda Johnstone

2022/73	1.	<p><u>Apologies for Absence</u></p> <p>Dr David Semple, Ms Ann Auld, Dr Tyra Smyth</p>	
2022/74	2.	<p><u>Declaration of Interest</u></p> <p>There were no declarations of interest.</p>	
2022/75	3.	<p><u>Matters arising not covered elsewhere on the agenda</u></p> <p>a. <u>Ratification of minutes of meeting 20th April 2022</u></p> <p>The minute was accepted with the following amendment.</p> <p><u>RESUBMISSION</u></p> <p>Liraglutide (Saxenda®) SMC2455 This was noted and will be referred to dietetics for further advice.</p> <p>To be changed to</p> <p><u>RESUBMISSION</u></p> <p>Liraglutide (Saxenda®) SMC2455 This was noted and will be referred to weight management colleagues for further advice.</p> <p>b. <u>Steroid Emergency Cards</u></p> <p>Mrs Gilmour reported that she had agreed with Dr Burns that Dr Burns will write to all relevant clinicians to supply the cards where appropriate</p>	IM

	<p>c. <u>A guideline for Periprocedure management of coagulation.</u></p> <p>There was a fulsome discussion because this is an important but complex issue. Dr Malekian will meet with Dr Hung and Mrs Richardson (or Mrs Helen Barclay) to progress.</p> <p>d. <u>Symptomatic Relief Policy</u></p> <p>The update was agreed and Mrs Brankin will arrange for it to be published on the clinical guidelines website/APP.</p> <p>e. <u>Catheter Directed Thromolysis</u></p> <p>Dr Malekian reported that he had given feedback to the lead author and the guideline will come back to the ADTC in due course.</p>	<p>MM</p> <p>PB</p>
<p>2022/76 4.</p>	<p><u>SMC Advice</u></p> <p><u>FULL SUBMISSIONS</u></p> <p>Ixekizumab (Taltz®) SMC2440 This was noted.</p> <p>Tepotinib (Tepmetko®) SMC2457 This was noted.</p> <p><u>NON SUBMISSION</u></p> <p>Ruxolitinib (Jakavi®) SMC2498 This was noted.</p> <p><u>Update on the interim assessment approach in response to COVID-19</u></p> <p>This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for the submissions noted below will be published on the SMC website on Monday 13 June 2022.</p> <p><u>FULL SUBMISSIONS</u></p> <p>Abrocitinib (Cibinqo®) SMC2431 This was noted and will be referred to dermatology specialists.</p> <p>Relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg film-coated tablets (Ryeqo®) SMC2442 This was noted and will be referred to gynaecology specialists.</p> <p><u>ABBREVIATED</u></p> <p>Lenvatinib (Kisplxy®) SMC2476 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p>	

	<p><u>AMENDED ADVICE</u></p> <p>Ropeginterferon alfa-2b (Besremi®) SMC2421 This was noted.</p> <p>Pembrolizumab (Keytruda®) SMC2420 This was noted.</p> <p>Dapagliflozin (Forxiga®) SMC2428 This was noted.</p> <p>Daratumumab (Darzalex®) SMC2416 This was noted.</p> <p><u>OUTWITH REMIT DECISIONS (BASED ON CRITERION 14)</u></p> <p>Emtricitabine / tenofovir alafenamide (Descovy®) This was noted.</p>	
2022/77 5.	<p><u>SMC follow up</u></p> <p>Mrs McGoff talked the Committee through the SMC follow up which had been previously circulated. Feedback and clinical protocols are expected on a number of items in due course.</p>	CMcG
2022/78 6.	<p><u>Lanarkshire Formulary</u></p> <p>Mrs McGoff raised four formulary amendments. The first three related to the addition of bempedoic acid, bempedoic acid with ezetimibe and inclisiran to Chapter 3 of the Formulary. These are included as specialist initiation treatment options in the NHS Lanarkshire guideline ‘Management of Cholesterol in Adults’ previously ratified by the ADTC.</p> <p>The fourth was the addition of a statement under the oxybutynin entry in Chapter 7 to inform users of the Formulary that both strengths of modified release oxybutynin tablets are being discontinued in July 2022. The previous statement advising modified release tablets are acceptable following specialist advice has been removed.</p> <p>The Committee approved the above amendments.</p>	CMcG
2022/79 7.	<p><u>Clinical Protocols</u></p> <p>a. <u>Antibiotic Policies</u></p> <p>Dr Dundas explained the guidelines and drew attention to the inclusion of the Paediatric Aminoglycoside Antibiotic patient/carers information leaflet.</p> <p>The guidelines for gentamicin and vancomycin were agreed subject to removal of the “Pharmacy Department” annotation on page 1 and inclusion of the standard phrases for approval by the AMC and ADTC.</p> <p>The update for Sexual health was also agreed.</p>	SD

	<p>The update for respiratory infections was agreed subject to an update on the symptoms for Covid infection and exclusion of the reference to medicated lozenges.</p> <p>b. <u>NHS Lanarkshire Vasculitis Protocol</u></p> <p>Mrs Richardson will share detailed comments and Dr Malekian will feed these back to the author. This will include the need for clarity about patient monitoring.</p>	GR MM
2022/80 8.	<p><u>ADTC New Medicines Decisions</u></p> <p>This was noted.</p>	CMcG
2022/81 9.	<p><u>Unlicensed Medicines</u></p> <p>There was nil to note at today's meeting</p>	
2022/82 10.	<p><u>Patient Group Directions</u></p> <p>a. <u>Patient Group Direction For The Administration Of Medicines Included In The End Of Life Care PGD Formulary By Approved Healthcare Professionals Working Within NHS Lanarkshire</u></p> <p>Mrs Johnstone explained the experience with this PGD and it was approved.</p> <p>b. <u>Update of Review dates processes</u></p> <p>The outcome of the meeting to discuss this issue were noted and the prospect of establishing a business case will be debated at the next NMP Committee.</p> <p>c. <u>Community optometrist initiation of aspirin for TIA</u></p> <p>This was approved subject to:</p> <ul style="list-style-type: none"> a. Correction of a typo so that it is clear that this only applies to treatment of TIA b. Inclusion of detail within the training programme that all community optometrists should be directed to the BNF to check for every antiplatelet or anticoagulant the patient may be receiving. <p>There was also discussion and agreement that routes and timescales for subsequent patient assessment and prescribing of atorvastatin were appropriate.</p> <p>There was further interest in finding if a similar PGD or alternative service was in place in any other HB. Mr Lindsay will check this with Mr Munro.</p>	LJ GL GL

2022/83 11.	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p> <p>This was noted.</p>	
2022/84 12	<p><u>Regional Cancer Advisory Network</u></p> <p>There was nil to note at today's meeting.</p>	
2022/85 13.	<p><u>Patient Safety Alerts</u></p> <p>There was nil to note at today's meeting.</p>	
2022/86 14.	<p><u>Lay member related items</u></p> <p>There was nil to note at today's meeting.</p>	
15.	<p><u>ADTCC Correspondence</u></p> <p>a. Access to Medicines for extremely rare conditions</p> <p>This was noted.</p> <p>b. Sapropterin Update</p> <p>It was agreed that the proposals were pragmatic and did not set a precedent. Mr Lindsay will respond to the ADTCC to say that NHS Lanarkshire are supportive.</p> <p>c. MHRA Early Access to Medicines Scheme: Current scheme for Risankizumab EAMS number 41042/0007</p> <p>This was noted.</p> <p>d. ADTCC Forum Agenda 11th May</p> <p>Mr Linday fed back on the issues most relevant to the NHS Lanarkshire ADTC. These included:</p> <ul style="list-style-type: none"> • Plans for a meeting between the ADTCC and Chairs/Prof Secretaries of HB ADTCs • The development of a Scotland wide Teratogenic Advisory Group • Priorities for SAPG including OPAT and penicillin allergy delabelling • A new members "call" for SMC/NDC • A comprehensive update from Scottish Government including plans for an update to CEL 17, and work in relation to HRT, Controlled Drugs, Cannabis based medicines and the Teratogenic Advisory Group. The prioritisation and timescales will be determined by workforce capacity. 	GL

2022/87 16.	Pharmacy & NMAHP Prescribing Governance There was nil to note at todays meeting.	PB
2022/88 17.	<u>AOCB</u> a. <u>Homecare capacity</u> Mrs Richardson informed the committee of this issue which is being addressed via the Acute Divisional Management Team. b. <u>Formulary Network Forum</u> Mrs Maroni relayed a summary of the latest Formulary Network Forum discussions. The summary was written by a member of the Medicines Guidance and Policy Team who attended the forum meeting. Topics included work related to: <ul style="list-style-type: none"> • statin intolerance pathways • CEL 17 update • Truvada® and Descovy® • Utrogestan® • Liraglutide This was useful and will be a regular quarterly contribution to our meetings.	
2022/89 18.	<u>Date of next meeting</u> Wednesday 15 th June 2022 10am @ Microsoft Teams	